AzTrials
AzTrials

Cerebral OxygenationOXYSENIORNCT04045444

Cerebral Oxygenation During Gait in Elderly

A study testing walking and cognitive task in people with Cerebral Oxygenation, run by Centre Hospitalier Régional d'Orléans at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Ageing is accompanied by a cognitive decline altering gait and increasing the risk of falling. Physical activity could reduce this cognitive decline by an improvement in the oxygen supply to the brain. Read more about this study

Who is it for?
Ages 18 to 30 yearsHealthy volunteers can take part
Conditions the study is for
Cerebral Oxygenation
What is being tested?
walking and cognitive task
Could I receive a placebo?
No, everyone receives an active treatment
How many people
117 participants
Where
1 siteFrance
Study dates
25 Feb 2019to 20 Apr 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 30 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • men and women non active young people and men and women non active old people : practice less than one hour of physical activity per week
  • men and women active old people: practice at least 3 hours of physical activity per week
  • Non-Inclusion Criteria :
  • For all subjects:
  • Resting electrocardiographic abnormality, Systolic blood pressure >16
  • Heart disease, recent and unusual shortness of breath or needing several pillows to sleep at night, effort/rest chest pain, palpitations with effort, history of discomfort with effort
Show all 22Show fewer
  • Respiratory failure
  • Disabling rheumatological pathology for walking
  • Neuro-progressive disease or sequelae
  • Perceptual disorders
  • Medication (neuroleptics, psychotropic treatment modifying alertness) potentially having an impact on walking
  • Thickness of the skin fold at the vast lateral area greater than 15 mm
  • Inability of the volunteer to perform the Random Generation of Numbers task for at least 1 min or frequency of enunciation numbers during the Random Generation of Numbers task > 4/s
  • Refusal to sign informed consent
  • For the young sedentary group (woman and man) and the senior group (woman and man, sedentary and active):
  • -Subjective health > 3 out of 5
  • For the senior group (woman and man, sedentary and active):
  • Mini-Mental State Evaluation (MMSE) score < 24
  • Geriatric Depression Scale (GDS) score > 10
  • For the Parkinson group (woman and man):
  • Presence of a freezing or clinically embarrassing festination (walking disorder)
  • Score of Hoehn and Yahr ≥III

Who cannot join

  • -Inability of the volunteer to walk on the treadmill at a speed of 3 km/h without assistance (stand at the helm or ask for help)

Trial locations and contacts

1 site in 1 country.

France1 site
  • CHR Orléans

    Orléans, 45067

Other trials in France

About this study

Official title: Physical Activity Level and Cerebral Oxygenation During Gait in Old People

Ageing is accompanied by a cognitive decline altering gait and increasing the risk of falling. Physical activity could reduce this cognitive decline by an improvement in the oxygen supply to the brain. At the moment, the effect of physical activity on brain oxygenation during walking in elderly has never been described. Moreover, the increase in cognitive request during a dual task could lead to an increase in the risk of falling. In this context, the investigators of Orleans's hospital want to examine the effect of the physical activity level of elderly on their brain oxygenation during walking and during a dual task.

Moreover, Parkinson' patients could display an impairment of gait and cognitive function. Attentional task and dual task situation are particularly impaired in this pathology. This is why the investigators of Orleans's hospital want to also examine cerebral activation of these patients during walking and during a dual task.

The hemodynamic cerebral activation will be studied using the near infrared spectroscopy at the level of the prefrontal cortex. This non-invasive technic allows the evaluation of the regional oxyhemoglobin and deoxyhemoglobin variations induced by cerebral activation.

Read the detailed description

The main aim of the study is to determine the effect of the physical activity level on variations of the pre-frontal oxygenation during walking and during a dual task in elderly. The other aims are to study the effects of age, gender and the Parkinson' disease on variations of the pre-frontal oxygenation during walking and during a dual task in elderly.

For that, 160 participants (females and males) will be included and 8 groups will be constituted (woman and man non active young people, woman and man non active old people, woman and man active old people, woman and man patients with Parkinson's disease).

Every participants will performed a set of 6 tasks of 2 minutes. Each task will be separated by a 2 minutes resting period. The tasks will be a cognitive task, a control cognitive task, walking at 3 kilometers/hour, walking while doing the cognitive task, walking at the preferred speed, walking at the preferred speed while doing the cognitive task.

During the set, prefrontal oxygenation will be measured using the near infrared spectroscopy.

Being tested
walking, cognitive task
Keywords
physical activity, cognitive function, elderly, parkinson, muscle oxygenation, gait parameters
Medical subject headings
Motor Activity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • walkingOther

    Every participants will performed a set of tasks of 2 min. Each task will be separated by a 2 min resting period. The tasks will be walking at 3 km/h, walking while doing the cognitive task, walking at the preferred speed, walking at the preferred speed while doing the cognitive task.

  • cognitive taskOther

    Every participants will performed a set of tasks of 2 min. Each task will be separated by a 2 min resting period. The tasks will be a cognitive task, a control cognitive task.

Study groups in NCT04045444
Study groupRoleWhat they receive
women non active young peopleExperimentalwomen between 18 and 30 years practice less than 1h of physical activity per week
Receives: Other: walking; Other: cognitive task
men non active young peopleExperimentalmen between 18 and 30 years practice less than 1h of physical activity per week
Receives: Other: walking; Other: cognitive task
women non active old peopleExperimentalwomen between 60 and 85 years practice less than 1h of physical activity per week
Receives: Other: walking; Other: cognitive task
men non active old peopleExperimentalmen between 60 and 85 years practice less than 1h of physical activity per week
Receives: Other: walking; Other: cognitive task
women active old peopleExperimentalwomen between 60 and 85 years practice at least 3h of physical activity per week
Receives: Other: walking; Other: cognitive task
men active old peopleExperimentalmen between 60 and 85 years practice at least 3h of physical activity per week
Receives: Other: walking; Other: cognitive task
women with parkinson's diseaseExperimentalwomen between 60 and 85 years presence of the disease according to the criteria of the UK Parkinson Disease Brain Bank
Receives: Other: walking; Other: cognitive task
men with parkinson's diseaseExperimentalmen between 60 and 85 years presence of the disease according to the criteria of the UK Parkinson Disease Brain Bank
Receives: Other: walking; Other: cognitive task

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. concentration of cerebral oxyhemoglobin

    The objective is to determine the effect of physical activity level on variations in cerebral oxygenation (combination of concentration of oxyhemoglobin and deoxyhemoglobin) during simple walking and during double task walking in elderly people.

    Cerebral oxygenation will be determined continuously at rest and during walking. She will be measured non-invasively with a near infrared spectrometry system (Oxymon, Artinis Medical system, Netherlands). This system measures the evolution of the concentration of OxyHb and DeoxyHb by measuring the absorption of light into tissues.

    The measurement of cerebral oxygenation will evaluate the hemodynamic response at the regional level during the cognitive task, the simple walking task and the dual task.

    Measured: day 1

  2. concentration of cerebral deoxyhemoglobin

    The objective is to determine the effect of physical activity level on variations in cerebral oxygenation (combination of concentration of oxyhemoglobin and deoxyhemoglobin) during simple walking and during double task walking in elderly people.

    Cerebral oxygenation will be determined continuously at rest and during walking. She will be measured non-invasively with a near infrared spectrometry system (Oxymon, Artinis Medical system, Netherlands). This system measures the evolution of the concentration of OxyHb and DeoxyHb by measuring the absorption of light into tissues.

    The measurement of cerebral oxygenation will evaluate the hemodynamic response at the regional level during the cognitive task, the simple walking task and the dual task.

    Measured: day 1

Secondary outcomes (6)
  1. concentration of muscular oxyhemoglobin

    Study the effect of age and gender on muscular oxygenation during the simple walk and during the double task operation.

    This will be measured non invasively with a near infrared spectrometry system (Oxymon, artinis medical system, netherlands)

    Measured: day 1

  2. concentration of muscular deoxyhemoglobin

    Study the effect of age and gender on muscular oxygenation during the simple walk and during the double task operation.

    This will be measured non invasively with a near infrared spectrometry system (Oxymon, artinis medical system, netherlands)

    Measured: day 1

  3. measurement of cognitive performance using random number generation task

    This task is for the particpants to state a number between 0 and 9 randomly at the fastest possible frequency by avoiding to state two consécutives digits one after the other (eg not to stay 5 then 6) . this task will be realised during simple walk and double task.

    Measured: day 1

  4. cardiac frequency

    Study the effect of age and gender on cardiac frequency during the simple walk and during the double task operation

    Measured: day 1

  5. Step width: distance between the middle support point of each foot with optogait system

    Study the effect of age on walking parameters during the simple walk and during the double task operation

    Measured: day 1

  6. Scale of perceived difficulties for perception of effort

    This scale consists of 15 steps of ladder associated with verbal information (ranging from extremely easy for 2 to extremely difficult for 14) allowing the subjective descritpion of the difficulty of the task. With this scale the effect of gender on the perception of effort during the simple walk and during the double task will be studied.

    Measured: day 1

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Aug 2019
  2. Study start25 Feb 2019
  3. Primary completion20 Apr 2021
  4. Study completion20 Apr 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Non-randomised
Intervention model
Single group
Masking
None (open label)
Enrolment
117 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04045444
Sponsor's protocol ID
CHRO-2018-11
Acronym
OXYSENIOR
Status last verified
Aug 2021
First submitted
21 Feb 2019
Last updated
1 Sep 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Anderton BH. Ageing of the brain. Mech Ageing Dev. 2002 Apr;123(7):811-7. doi: 10.1016/s0047-6374(01)00426-2.

    PubMed 11869738
  • Andres P, Van der Linden M. Age-related differences in supervisory attentional system functions. J Gerontol B Psychol Sci Soc Sci. 2000 Nov;55(6):P373-80. doi: 10.1093/geronb/55.6.p373.

    PubMed 11078107
  • Asllani I, Habeck C, Borogovac A, Brown TR, Brickman AM, Stern Y. Separating function from structure in perfusion imaging of the aging brain. Hum Brain Mapp. 2009 Sep;30(9):2927-35. doi: 10.1002/hbm.20719.

    PubMed 19172645
  • Azulay JP, Van Den Brand C, Mestre D, Blin O, Sangla I, Pouget J, Serratrice G. [Automatic motion analysis of gait in patients with Parkinson disease: effects of levodopa and visual stimulations]. Rev Neurol (Paris). 1996 Feb;152(2):128-34. French.

    PubMed 8761620

Questions about this trial

What is this clinical trial studying?

A study testing walking and cognitive task in people with Cerebral Oxygenation, run by Centre Hospitalier Régional d'Orléans at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 22 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 1 Sep 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

concentration of cerebral oxyhemoglobin (time frame: day 1). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04045444, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Sep 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in